BCM
JAZZ icon

Bayesian Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bayesian Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,269
Closed -$253K – 840
2024
Q3 		$253K Buy
+2,269
New +$249K 0.03% 516
2023
Q4 		– Sell
-4,858
Closed -$629K – 886
2023
Q3 		$629K Buy
4,858
+3,000
+161% +$400K 0.07% 320
2023
Q2 		$230K Sell
1,858
-8,029
-81% -$1.08M 0.02% 604
2023
Q1 		$1.45M Buy
9,887
+699
+8% +$103K 0.18% 167
2022
Q4 		$1.46M Buy
9,188
+3,600
+64% +$528K 0.21% 105
2022
Q3 		$745K Buy
+5,588
New +$850K 0.15% 186
2021
Q4 		– Sell
-4,889
Closed -$637K – 452
2021
Q3 		$637K Sell
4,889
-3,311
-40% -$500K 0.18% 149
2021
Q2 		$1.46M Sell
8,200
-1,111
-12% -$192K 0.38% 72
2021
Q1 		$1.53M Buy
+9,311
New +$1.53M 0.35% 71
2019
Q3 		– Sell
-16,007
Closed -$2.28M – 599
2019
Q2 		$2.28M Buy
+16,007
New +$2.15M 0.47% 53
2018
Q3 		– Sell
-1,300
Closed -$224K – 712
2018
Q2 		$224K Buy
+1,300
New +$212K 0.05% 491
2018
Q1 		– Sell
-1,862
Closed -$251K – 708
2017
Q4 		$251K Buy
+1,862
New +$258K 0.05% 454
2017
Q1 		– Sell
-7,600
Closed -$829K – 553
2016
Q4 		$829K Buy
+7,600
New +$847K 0.21% 181
2016
Q3 		– Sell
-1,700
Closed -$240K – 430
2016
Q2 		$240K Buy
+1,700
New +$251K 0.14% 275

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bayesian Capital Management's JAZZ Position: Q4 2024 in Review

Bayesian Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 2,269 shares — an estimated $253K sold.

Bayesian Capital Management first reported a position in JAZZ in Q2 2016 and held it in 14 quarters. The position peaked at $2.28M in Q2 2019. 509 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • Bayesian Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 2,269 Jazz Pharmaceuticals shares in Q4 2024, an estimated $253K.
  • Bayesian Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 14 quarters.
  • Bayesian Capital Management's Jazz Pharmaceuticals position peaked at $2.28M in Q2 2019.
  • 509 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.